Consensus Astria Therapeutics, Inc.

Equities

ATXS

US04635X1028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
9 ^USD	-6.64%		-14.69%	+17.19%

Apr. 23	HC Wainwright Cuts Astria Therapeutics' Price Target to $16 From $18, Maintains Buy Rating	MT
Apr. 09	Astria Therapeutics, Inc. Appoints Sunil Agarwal to the Board of Directors and Member of the Science and Technology Committee	CI

Evolution of the average Target Price on Astria Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ddc5111e7217897a53738.NOQwcWPhxayX1op16Re9PgnhabqJZ7X9EcwNZqqUmY4.ZrcJPDPS9d_7huUGjHjJfGyADtPIIsCwd_g0JcHi7uJ1snkjBraS6dPh6Q~41952dc95aa8b5e7cf7373505056845c

Analyst Recommendations on Astria Therapeutics, Inc.

HC Wainwright Cuts Astria Therapeutics' Price Target to $16 From $18, Maintains Buy Rating	Apr. 23	MT
Wedbush Raises Astria Therapeutics' PT to $22 From $17 After Reporting Top-Line Phase 1/2 ALPHA-STAR Results for STAR-0215 Program; Maintains Outperform Rating	Mar. 26	MT
Oppenheimer Adjusts Astria Therapeutics Price Target to $25 From $30, Maintains Outperform Rating	Nov. 15	MT
Wedbush Trims Astria Therapeutics' Price Target to $17 From $18, Keeps Outperform Rating	Nov. 13	MT
Wedbush Adjusts Price Target on Astria Therapeutics to $18 From $25, Maintains Outperform Rating	23-10-13	MT
HC Wainwright Adjusts Astria Therapeutics Price Target to $18 From $20, Maintains Buy Rating	23-10-12	MT
Wedbush Trims Astria Therapeutics' Price Target to $25 From $26, Keeps Outperform Rating	23-08-08	MT
Evercore ISI Initiates Coverage on Astria Therapeutics With Outperform Rating, $18 Price Target	23-03-28	MT
Wedbush Adjusts Price Target on Astria Therapeutics to $26 From $27, Keeps Outperform Rating	23-03-22	MT
HC Wainwright Adjusts Astria Therapeutics Price Target to $20 From $13, Maintains Buy Rating	22-12-19	MT
Wedbush Adjusts Astria Therapeutics Price Target to $27 From $16, Maintains Outperform Rating	22-12-15	MT
Wedbush Lifts Price Target on Astria Therapeutics to $16 From $15, Keeps Outperform Rating	22-08-10	MT
Wedbush Adjusts Astria Therapeutics' Price Target to $15 From $16, Keeps Outperform Rating	21-11-11	MT
ASTRIA THERAPEUTICS : Jefferies Starts Astria Therapeutics at Buy with $20 Price Target	21-09-29	MT
ASTRIA THERAPEUTICS : Oppenheimer Raises Astria Therapeutics' PT to $30 from $5 After 1 for 6 Reverse Stock Split, Keeps Outperform Rating	21-09-24	MT
CATABASIS PHARMACEUTICALS : Wedbush Initiates Catabasis Pharmaceuticals at Outperform Rating With $16 Price Target	21-09-02	MT
CATABASIS PHARMACEUTICALS : HC Wainwright Upgrades Catabasis Pharmaceuticals to Buy From Neutral; Price Target is $13	21-08-25	MT
CATABASIS PHARMACEUTICALS : Ladenburg Thalmann Starts Catabasis Pharmaceuticals at Buy With $6 Price Target	21-05-12	MT
CATABASIS PHARMACEUTICALS : Oppenheimer Upgrades Catabasis Pharmaceuticals to Outperform From Perform, $5 Price Target	21-03-11	MT
CATABASIS PHARMACEUTICALS : Oppenheimer Upgrades Catabasis Pharmaceuticals to Outperform from Perform, Sets $5 Price Target	21-03-11	MT
CATABASIS PHARMACEUTICALS : Wedbush Downgrades Catabasis Pharmaceuticals to Neutral From Outperform, Adjusts PT to $1.15 From $15 on Edasalonexent/DMD Discontinuation	20-11-02	MT